Enhancing professional updates in assisted reproduction
Attending the seminar was Dr. Nguyen Thi My Dung, specialist level II – head of the department of assisted reproduction & andrology, along with numerous doctors, experts, and midwives from Hanoi obstetrics and gynecology hospital.
Representing Eurofins GENTIS, MSc. Nguyen Van Huynh – head of R&D, delivered a presentation titled: “Overview of PGT-M testing at Eurofins GENTIS.” The presentation attracted strong interest and active discussions from attending experts, contributing to improved professional knowledge and practical application in treatment.
PGT-M – a solution for genetic disease screening at the embryo stage
PGT (preimplantation genetic testing) is a genetic analysis performed before embryo transfer, helping select the best embryos genetically, free from chromosomal abnormalities or disease-causing genes.
PGT-M is specifically applied for couples at risk of passing single-gene disorders to their offspring, enabling detection and exclusion of affected embryos.
Common groups of single-gene genetic disorders:
Autosomal recessive disorders:
- Thalassemia (HBA, HBB)
- Spinal muscular atrophy (SMN1)
- Congenital deafness (GJB2)
- Citrin deficiency (SLC25A13)
Autosomal dominant disorders:
- Achondroplasia (FGFR3)
- Marfan syndrome (FBN1)
- Familial hypercholesterolemia (LDLR)
- Polycystic kidney disease (PKD1, PKD2)
X-linked disorders:
- Duchenne muscular dystrophy (DMD)
- Hemophilia A, B (F8, F9)
- G6PD deficiency
- Fabry disease (GLA)
Key highlights of PGT-M testing at Eurofins GENTIS
PGT-M testing at Eurofins GENTIS is developed and optimized according to international standards, offering several outstanding advantages:
- Application of bioinformatics software to select genetic markers suitable for the Vietnamese population, optimizing analysis time and cost
- Procedures compliant with ESHRE 2020 recommendations, ensuring standardization and high reliability
- CAP-accredited laboratory for PGT and NIPT services with strict quality control
- Capability to analyze more than 100 genes/diseases, meeting diverse clinical needs
- Combination of direct mutation detection and linkage analysis methods to enhance accuracy
Optimized turnaround time:
- Thalassemia: approximately 12 days
- Other rare diseases: from 20–60 days
Promoting professional collaboration – enhancing treatment quality
Through this scientific seminar, Eurofins GENTIS reaffirmed its commitment to partnering with healthcare institutions in updating advanced testing technologies, contributing to improved diagnostic and treatment outcomes in assisted reproduction.
The close collaboration between Eurofins GENTIS and Hanoi obstetrics and gynecology hospital not only brings professional value but also expands access to modern genetic solutions for patients, aiming toward the goal of giving birth to healthy babies from the very beginning.
